0001127602-21-028715.txt : 20211109
0001127602-21-028715.hdr.sgml : 20211109
20211109163655
ACCESSION NUMBER: 0001127602-21-028715
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211105
FILED AS OF DATE: 20211109
DATE AS OF CHANGE: 20211109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Andres Juan
CENTRAL INDEX KEY: 0001760670
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 211392811
MAIL ADDRESS:
STREET 1: C/O MODERNA, INC.
STREET 2: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2021-11-05
0001682852
Moderna, Inc.
MRNA
0001760670
Andres Juan
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
See remarks
Common Stock
2021-11-05
4
M
0
5000
12.21
A
5000
D
Common Stock
2021-11-05
4
S
0
5000
240.00
D
0
D
Common Stock
2021-11-08
4
M
0
10000
14.22
A
10000
D
Common Stock
2021-11-08
4
M
0
5000
12.21
A
15000
D
Common Stock
2021-11-08
4
S
0
15000
233.13
D
0
D
Stock Option (Right to Buy)
12.21
2021-11-05
4
M
0
5000
0
D
2027-08-29
Common Stock
5000
120000
D
Stock Option (Right to Buy)
14.22
2021-11-08
4
M
0
10000
0
D
2028-02-28
Common Stock
10000
58629
D
Stock Option (Right to Buy)
12.21
2021-11-08
4
M
0
5000
0
D
2027-08-29
Common Stock
5000
115000
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
This option is fully vested and exercisable.
25% of this option will vest and become exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.
Chief Technical Operations and Quality Officer
/s/ Brian Sandstrom, as Attorney-in-Fact
2021-11-09